Comparative Tests of Flu Vaccination Phone Messages

Status Completed

Clinical Trial Summary

This project is a partnership between Emmi Solutions, a private company that delivers health promotion messages to employees of client organizations, and the University of Michigan and affiliated academic investigators. In particular, Emmi sends out pre-recorded and interactive telephone calls on behalf of their healthcare clients to promote influenza vaccination each Fall. The collaboration will design various scripts (based on established risk communication, behavior change, and behavioral economic principles) to be pre-recorded and sent out on these calls on a randomized basis (with approval by client organizations), with the number of arms to vary based on the size of each client's participant list (to ensure sufficient statistical power within each client's sample). Emmi will deliver the calls and track individual responses to questions posed during the call. Emmi will then provide a de-identified dataset to the academic research team for analysis to determine whether any scripts provided greater or lesser effects to people's their motivations to get a flu vaccination.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Influenza, Human

Clinical Trial Details

NCT number	NCT03332992
Study type	Interventional
Source	University of Michigan
Contact
Status	Completed
Phase	N/A
Start date	November 11, 2017
Completion date	April 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03275389` - A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years	Phase 1
Completed	`NCT03442582` - Afluria Pregnancy Registry
Completed	`NCT05981846` - A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19	Phase 2
Completed	`NCT05044195` - A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age	Phase 3
Completed	`NCT02914275` - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.	Phase 3
Completed	`NCT04590066` - Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy	N/A
Recruiting	`NCT03778203` - Development of Childhood Anti-influenza Immunity	Phase 4
Completed	`NCT04527614` - Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection	N/A
Terminated	`NCT03658629` - Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults	Phase 2
Completed	`NCT05269290` - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections	Phase 3
Completed	`NCT06385821` - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus	Phase 3
Withdrawn	`NCT02883972` - Childhood Influenza Immunisation Invitation Trial in Schools	N/A
Completed	`NCT02867358` - A Clinical Trial of KT07 Capsule in the U.S.A	Phase 2
Completed	`NCT02998996` - Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU	Phase 1/Phase 2
Completed	`NCT02984280` - Specific Respiratory Infections as Triggers of Acute Medical Events	N/A
Completed	`NCT02545543` - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age	Phase 3
Completed	`NCT02621164` - Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents	Phase 3
Completed	`NCT02243774` - Mail Outreach To Increase Vaccination Acceptance Through Engagement	N/A
Completed	`NCT02212106` - A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years	Phase 4
Completed	`NCT02344134` - Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects	Phase 3